DMAAR NASDAQ
Drugs Made In America Acquisition Corp. Rights
1W: +2.0%
1M: -1.9%
3M: +15.9%
YTD: -28.4%
1Y: -41.5%
$0.13
+0.00 (+0.87%)
Weekly Expected Move ±21.1%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$287.8M
52W Range0.04-0.2299
Volume16,000
Avg Volume48,574
Beta3.90
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORoger Bendelac
Employees2
SectorFinancial Services
IndustryShell Companies
IPO Date2026-01-13
Websitedmaacorp.com
420 Lexington Avenue
New York, NY 10170
US
New York, NY 10170
US
+1 212 906 1222
About Drugs Made In America Acquisition Corp. Rights
Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company (SPAC), established with the primary objective of identifying and acquiring one or more active businesses or their assets. The company plans to achieve these acquisitions through various transactional structures, including mergers, exchanges of equity shares, direct asset purchases, stock acquisitions, or broader corporate reorganizations.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Drugs Made In Americ | P-Purchase | 30,000 | — | 2025-02-18 |
| Drugs Made In Americ | P-Purchase | 30,000 | — | 2025-02-18 |
| Stockwell Lynn | P-Purchase | 30,000 | — | 2025-02-18 |
| Stockwell Lynn | P-Purchase | 30,000 | — | 2025-02-18 |
| Drugs Made In Americ | P-Purchase | 400,000 | — | 2025-01-29 |